Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10813-10822

  Yokoyama, Yumi ^a   Sedgewick, Gerald ^a   Ramakrishnan, S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; GREEN FLUORESCENT PROTEIN; SMALL INTERFERING RNA; VERY LATE ACTIVATION ANTIGEN 5;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD29; CELL LINE, TUMOR; ENDOSTATINS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTEGRIN ALPHA5; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PERITONEUM; PROTEIN BINDING;

EID: 36348939437     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0172     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
2. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
3. 3 integrins in ovarian cancer. Gynecol Oncol 1995;58:216-25.
4. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
5. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-87.
6. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
7. MacDonald NJ, Shivers WY, Narum DL, et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-6.
8. Zeng X, Chen J, Miller YI, et al. Endostatin binds biglycan and LDL and interferes with LDL retention to subendothelial matrix during atherosclerosis. J Lipid Res 2005;46:1849-59.
9. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin a5h1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002;62:5580-9.
10. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci US A 2001;98:1024-9.
11. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-22.
12. Yokoyama Y, Ramakrishnan S. Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer 2007. Published online.
13. Ramakrishnan S, Olson TA, Bautch VL, et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56: 1324-30.
14. Burleson KM, Casey RC, Skubitz KM, et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 2004;93:170-81.
15. Yokoyama Y, Ramakrishnan S. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer 2004;111:839-48.
16. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
17. Yokoyama Y, Dhanabal M, Griffioen AW, et al. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-6.
18. Yokoyama Y, Ramakrishnan S. Improved biological activity of a mutant endostatin containing a single amino-acid substitution. Br J Cancer 2004;90:1627-35.
19. Subramanian IV, Ghebre R, Ramakrishnan S. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther 2005;12:30-8.
20. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci US A 1999;96:2811-6.
21. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410.
22. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997;151:1417-23.
23. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-33.
24. 1 integrins at the surface of mesothelial cells: a potential attachment site of endometrial cells. Fertil Steril 2000;74:579-84.
25. 1-integrin-mediated interaction with type I collagen. Invasion Metastasis 1998;18:15-26.
26. 1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin Exp Metastasis 2000;18:67-75.
27. Mendoza L, Valcarcel M, Carrascal T, et al. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Cancer Res 2004;64:304-10.
28. Te Velde EA, Reijerkerk A, Brandsma D, et al. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer 2005;92:729-35.
29. Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004;64:1781-7.
30. Livant DL. Targeting invasion induction as a therapeutic strategy for the treatment of cancer. Curr Cancer Drug Targets 2005;5:489-503.